Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens

EMERALD 48-week safety and efficacy results published in The Lancet HIV and to be presented at IDWeek
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news